Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients aged 19 years or older~2. Patients with pathologically or cytologically confirmed advanced solid tumor which is refractory to standard treatment or for which there is no standard therapy~3. ECOG performance status ≤ 2~4. Life expectancy of ≥ 12 weeks~5. Adequate hematologic, hepatic and renal functions as follows:~   * ANC ≥ 1,500/µL (without G-CSF support within 2 weeks before IP administration)~  * Platelet ≥ 100,000/µL (without transfusion within 2 weeks before IP administration)~  * Hemoglobin ≥ 10.0 g/dL (without transfusion within 4 weeks before IP administration)~  * Serum creatinine ≤ 1.5 mg/dL or eGRF ≥ 60 mL/min/1.73 m2~  * AST and ALT ≤ 2.5 x ULN (AST and ALT ≤ 5 x ULN in the presence of liver metastasis or hepatocarcinoma)~  * Total bilirubin ≤ 1.5 x ULN (with exception of the case associated with Gilbert's syndrome)~  * PT and aPTT ≤ 1.5 x ULN~  * UPC \< 1.0 (g/g) (requiring if protein ≥ 1 positive (+) in urinalysis)~6. Patients who voluntarily give written informed consent~Exclusion Criteria:~1. Patients with hematologic malignancies including lymphoma~2. Chemo-, radio-chemo-, biologic-, immuno- or radiotherapy for advanced solid tumor within 4 weeks (or nitrosoureas, mitomycin within 6 weeks or targeted biological antibody within 8 weeks) before IP administration~3. Patients had received high-dose chemotherapy requiring hematopoietic progenitor cell support within 2 years before IP administration~4. Patients with symptomatic central nervous system (CNS) metastasis (patients who are radiologically and neurologically stable condition for ≥ 4 weeks and discontinued corticosteroids at least 4 week before IP administration are able to participate in this trial.)~5. History of deep vein thrombosis or pulmonary embolism within 1 year; Cytomegalovirus (CMV), Epstein-Barr virus (EBV), acute coronary syndrome (including unstable angina or myocardial infarction), or clinically significant cerebrovascular disease (including stroke) within 6 month; Major surgery requiring general anesthesia or respiratory assist within 4 weeks (or video-assisted thoracoscopic surgery or open-and-closed surgery within 2 weeks) before IP administration~6. Concurrent NYHA class III or IV heart failure, uncontrolled hypertension, poorly controlled arrhythmia, other clinically significant cardiovascular abnormalities at investigator's discretion (e.g. LVEF \< 50%, clinical significant abnormalities of heart wall, or cardiac muscle damage), known positive result for HIV or other uncontrolled active infection disease~7. Requirement for continuous non-steroidal anti-inflammatory drugs (NSAIDs) or systemic corticosteroids~8. Receiving anticoagulant, history of bleeding diathesis, massive hemoptysis, gastrointestinal hemorrhage, or peptic ulcer disease (\< 325 mg aspirin is acceptable)~9. History of severe drug hypersensitivity or hypersensitivity to IP or similar Mab~10. Pregnancy or breast-feeding~11. Women of childbearing potential (WOCBP) or men who are unwilling to use adequate contraception or be abstinent during the trial and for at least 2 months after the end of treatment~12. Patients who received investigational product or investigational device in other clinical trials within 3weeks prior to participation in this trial~13. Patients who cannot participate in this trial at the investigator's discretion

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YYB101 (Type: EXPERIMENTAL): Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).